News | December 16, 2009

University of Virginia Collaborates to Develop New Cardio Drugs

December 17, 2009 – The University of Virginia (UVa) in Charlottesville and AstraZeneca this week entered into a strategic research collaboration to enhance development of new treatments, primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

The collaborative preclinical research projects will focus on identifying disease mechanisms and biological targets that have the potential to be starting points for successful and commercially viable treatments of these diseases. The financial terms of the deal were not disclosed.

Atherosclerosis is one of the primary causes of heart diseases, stroke and often death in both men and women in western societies. All evidence suggests that this will increase further as risk factors such as poor diet, increased body weight, and a sedentary lifestyle all increase and the prevalence of obesity and diabetes mellitus reach epidemic proportions globally.

The traditional nonsurgical approach to managing CAD has been through treatment of risk factors such as dyslipidemia, hypertension, diabetes, obesity and others. New and innovative approaches, which act directly on the disease in the vessel wall to slow the progression of, regress, or stabilize the atherosclerotic plaque, could be important, especially when linked to novel biomarkers of vulnerable plaque.

“This is an area of high unmet medical need: atherosclerosis is a primary cause of cardiovascular morbidity and mortality,” said Bjorn Wallmark, vice president of cardiovascular and gastrointestinal research, AstraZeneca. “AstraZeneca is committed to finding innovative solutions. By partnering with the University of Virginia and working together on the complex biology of these diseases it increases the potential of delivering new treatment options.”

“We are very pleased to join AstraZeneca in advancing the science of cardiovascular research,” said Gary Owens, director of UVa’s Robert M. Berne Cardiovascular Research Center and UVa principal investigator of the AstraZeneca-UVa Alliance. “Our partnership has the potential to greatly speed up the development of novel drugs to treat diseases in several targeted areas, taking these projects years ahead in some cases.”

For more information: www.astrazeneca.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Overlay Init